ECSP11011132A - Compuesto amino pirazol - Google Patents

Compuesto amino pirazol

Info

Publication number
ECSP11011132A
ECSP11011132A EC2011011132A ECSP11011132A ECSP11011132A EC SP11011132 A ECSP11011132 A EC SP11011132A EC 2011011132 A EC2011011132 A EC 2011011132A EC SP11011132 A ECSP11011132 A EC SP11011132A EC SP11011132 A ECSP11011132 A EC SP11011132A
Authority
EC
Ecuador
Prior art keywords
pirazol
amino
compound
glioblastoma
leukemia
Prior art date
Application number
EC2011011132A
Other languages
English (en)
Spanish (es)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011132A publication Critical patent/ECSP11011132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EC2011011132A 2008-12-16 2011-06-15 Compuesto amino pirazol ECSP11011132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
ECSP11011132A true ECSP11011132A (es) 2011-07-29

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011132A ECSP11011132A (es) 2008-12-16 2011-06-15 Compuesto amino pirazol

Country Status (38)

Country Link
US (2) US7897600B2 (enExample)
EP (1) EP2379557B1 (enExample)
JP (1) JP5509217B2 (enExample)
KR (1) KR101300458B1 (enExample)
CN (1) CN102232075B (enExample)
AR (1) AR074240A1 (enExample)
AU (1) AU2009330503B2 (enExample)
BR (1) BRPI0923048A2 (enExample)
CA (1) CA2744714C (enExample)
CL (1) CL2011001445A1 (enExample)
CO (1) CO6331442A2 (enExample)
CR (1) CR20110341A (enExample)
CY (1) CY1113637T1 (enExample)
DK (1) DK2379557T3 (enExample)
DO (1) DOP2011000190A (enExample)
EA (1) EA019554B1 (enExample)
EC (1) ECSP11011132A (enExample)
ES (1) ES2396617T3 (enExample)
HN (1) HN2011001697A (enExample)
HR (1) HRP20120918T1 (enExample)
IL (1) IL213065A0 (enExample)
JO (1) JO2833B1 (enExample)
MA (1) MA32900B1 (enExample)
MX (1) MX2011006441A (enExample)
MY (1) MY158691A (enExample)
NZ (1) NZ592641A (enExample)
PA (1) PA8851101A1 (enExample)
PE (1) PE20110549A1 (enExample)
PL (1) PL2379557T3 (enExample)
PT (1) PT2379557E (enExample)
SG (1) SG172202A1 (enExample)
SI (1) SI2379557T1 (enExample)
SV (1) SV2011003949A (enExample)
TN (1) TN2011000292A1 (enExample)
TW (1) TWI440640B (enExample)
UA (1) UA104743C2 (enExample)
WO (1) WO2010074947A1 (enExample)
ZA (1) ZA201103942B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
US9127074B2 (en) * 2011-03-07 2015-09-08 Fondazione Telethon TFEB variants and uses thereof
JP6228113B2 (ja) * 2011-06-15 2017-11-08 ライフ・アンド・ブレイン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＬＩＦＥ ＡＮＤ ＢＲＡＩＮ ＧｍｂＨ グリア芽腫阻害化合物およびその使用
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
DK3179992T3 (da) 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
KR102611856B1 (ko) * 2016-11-17 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
CN1596255A (zh) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
SI1853602T1 (sl) 2005-02-16 2010-11-30 Astrazeneca Ab Kemične spojine
AU2006265840B2 (en) * 2005-07-01 2010-02-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US7776865B2 (en) * 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
TWI333953B (en) * 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
WO2008052734A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
CN101679412A (zh) 2007-05-23 2010-03-24 药典有限责任公司 作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
NZ592641A (en) 2013-01-25
TW201024301A (en) 2010-07-01
BRPI0923048A2 (pt) 2018-09-25
EA201170831A1 (ru) 2011-12-30
EA019554B1 (ru) 2014-04-30
DOP2011000190A (es) 2011-07-31
ES2396617T3 (es) 2013-02-22
AR074240A1 (es) 2011-01-05
CA2744714C (en) 2013-06-25
SI2379557T1 (sl) 2013-02-28
PA8851101A1 (es) 2010-07-27
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21
ZA201103942B (en) 2012-08-29
TN2011000292A1 (en) 2012-12-17
CY1113637T1 (el) 2016-06-22
IL213065A0 (en) 2011-07-31
KR101300458B1 (ko) 2013-08-30
US20100286139A1 (en) 2010-11-11
MX2011006441A (es) 2011-07-19
CR20110341A (es) 2011-07-13
US20100152181A1 (en) 2010-06-17
JO2833B1 (en) 2014-09-15
AU2009330503B2 (en) 2012-06-07
EP2379557A1 (en) 2011-10-26
HK1160109A1 (en) 2012-08-10
HN2011001697A (es) 2013-11-26
SG172202A1 (en) 2011-07-28
AU2009330503A1 (en) 2010-07-01
EP2379557B1 (en) 2012-10-31
CO6331442A2 (es) 2011-10-20
DK2379557T3 (da) 2012-12-17
PL2379557T3 (pl) 2013-03-29
WO2010074947A1 (en) 2010-07-01
MY158691A (en) 2016-10-31
JP2012512158A (ja) 2012-05-31
CN102232075B (zh) 2013-12-11
PE20110549A1 (es) 2011-08-04
PT2379557E (pt) 2013-01-14
CN102232075A (zh) 2011-11-02
TWI440640B (zh) 2014-06-11
KR20110084993A (ko) 2011-07-26
US7897600B2 (en) 2011-03-01
UA104743C2 (ru) 2014-03-11
CL2011001445A1 (es) 2011-11-11
CA2744714A1 (en) 2010-07-01
JP5509217B2 (ja) 2014-06-04
HRP20120918T1 (hr) 2012-12-31

Similar Documents

Publication Publication Date Title
CO6331442A2 (es) Compuesto amino pirazol
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201171367A1 (ru) Винилиндазолильные соединения
PH12016502066A1 (en) Methods of treating bladder cancer
MX373121B (es) Composiciones y metodos para el tratamiento de leucemia.
MX346924B (es) Compuestos de diarilhidantoina.
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
MX2009008222A (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
MX375325B (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
CY1117722T1 (el) Βελτιωμενη αγωγη του πολλαπλου μυελωματος
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
MX2015007054A (es) Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
EA201992557A1 (ru) Противоопухолевые соединения
MX2013013071A (es) Molecula paa el tratamiento de un transtorno inflamatorio.
CL2014001265A1 (es) Compuestos derivados de uracilo, inhibidores de la quinasa axl y c-met, utiles en el tratamiento del cancer.
UA100869C2 (ru) Лечение рака яичника с помощью соединения йодонитробензамида в комбинации с противоопухолевыми средствами
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου